Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire - Fri Nov 14, 5:00AM CST

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion...

INBX : 84.51 (-4.93%)
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire - Tue Nov 4, 3:01PM CST

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 84.51 (-4.93%)
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts PR Newswire - Thu Oct 23, 3:05PM CDT

SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 84.51 (-4.93%)
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts PR Newswire - Wed Oct 22, 3:01PM CDT

– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –

INBX : 84.51 (-4.93%)
Inhibrx Reports Second Quarter 2025 Financial Results PR Newswire - Wed Aug 13, 3:05PM CDT

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following...

INBX : 84.51 (-4.93%)
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire - Wed Oct 18, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 84.51 (-4.93%)
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 84.51 (-4.93%)
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...

INBX : 84.51 (-4.93%)
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire - Mon May 8, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong...

INBX : 84.51 (-4.93%)
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results PR Newswire - Mon Mar 6, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong...

INBX : 84.51 (-4.93%)

Barchart Exclusives

Nearly 45% of Its Float Is Being Sold Short. Should You Bet on iRobot Stock Here? Barchart - 36 minutes ago
iRobot stock pushes further up as meme enthusiasts continue to flock into the consumer robots specialist. Here’s why investors are recommended against chasing the rally in IRBT shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot